TLR7 and neoplasm: TLR7/8 agonist resiquimod (R848) can regulate tumor immune microenvironment by polarizing M2 macrophages into M1 macrophages and activating DC (Chen et al., 2020), further enhancing the immune system’s anti-tumor effect (Wei et al., 2021).